Di Gianfilippo Riccardo (Orcid ID: 0000-0003-2579-9464)
Wang Chin-Wei (Orcid ID: 0000-0001-9679-4121)
Xie Yuying (Orcid ID: 0000-0002-1049-2219)
Giannobile William V (Orcid ID: 0000-0002-7102-9746)
Wang Hom-Lay (Orcid ID: 0000-0003-4238-1799)

Title: **Effect of Laser-Assisted Reconstructive Surgical Therapy of Peri-implantitis on Protein Biomarkers and Bacterial Load**

Author: Riccardo Di Gianfilippo[1], Chin-Wei Wang[1,2,3], Yuying Xie[4,5], Janet Kinney[1], James Sugai[1], William V. Giannobile[1,6,7], Hom-Lay Wang[1],

[1]Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry

[2]School of Dentistry, College of Oral Medicine, Taipei Medical University

[3]Graduate Institute of Clinical Dentistry, National Taiwan University

[4]Department of Computational Mathematics, Science, and Engineering, Michigan State University

[5]Department of Statistics and Probability, Michigan State University

[6]Department of Biomedical Engineering, University of Michigan College of Engineering

[7]Department of Oral Medicine, Infection, and Immunity, Harvard School of Dental Medicine, Boston, MA USA

Corresponding author:

Chin-Wei (Jeff) Wang, DDS, DMSc.

Associate Professor, Taipei Medical University, College of Oral Medicine,

No.250, Wuxing St, Taipie City 11031 Taiwan

Adjunct Clinical Associate Professor, Department of Periodontics and Oral Medicine.

University of Michigan School of Dentistry. 1011 N. University Ave. Ann Arbor, MI 48109-1078 USA.

jeffwa@tmu.edu.tw

Short running title: Laser on peri-implant protein and bacterial biomarkers

Author contributions: All authors provided significant contribution for the realization of this study and approved the last version before submission. JW, HLW and WVG conceived the ideas; RDG, JK and JS collected the data; RDG, JW and YX analyzed the data; RDG and JW led the writing; JW, HLW and WVG supervised the study phases.

Count of words: 4950

Count of Figures: 4

Count of Supplementary documents: 4

Keywords: Lasers; Wound healing; Microbiology; Bone implant interactions; Clinical research, Clinical trials; Guided tissue regeneration, Bone regeneration; Periodontology

Abstract:

Objectives: This randomized clinical trial assessed changes in protein biomarker levels and bacterial profiles after surgical reconstructive therapy of peri-implantitis, and investigated whether the adjunctive use of Er:YAG laser impacts protein biomarker and microbial outcomes.

Materials and Methods: Twenty-four patients received surgical reconstructive therapy for peri-implantitis with guided bone regeneration following mechanical debridement with (test) or without (control) the adjunctive irradiation of Er:YAG laser. Bacterial and peri-implant crevicular fluid (PICF) samples were collected over 6 months and analyzed with bacterial qPCR and luminex multiplex assays.

Results: Surgical reconstructive treatment significantly affected the concentration of PICF protein biomarkers, including a 50% reduction of IL-1β between 2 and 4 weeks ($p < 0.0001$). Both MMP-9 ($p < 0.001$) and VEGF ($p < 0.05$) levels steadily decreased after treatment. In the laser group, the peak increase of IL-1β was attenuated at 2 weeks, followed by significant reduction of MMP-9 ($p < 0.01$) and VEGF ($p < 0.05$) across all follow-up appointments compared to the control non-laser group. The total bacterial load was reduced two weeks after treatment, especially in the laser group, but recolonized to presurgical levels after four weeks in both groups ($p < 0.01$). The composition of selective pathogens varied significantly over the follow-up, but recolonization patterns did not differ between groups.

Conclusions: Reconstructive therapy of peri-implantitis significantly altered PICF protein biomarker and microbial levels during the healing process. The adjunctive use of Er:YAG laser significantly modulated the inflammatory response through reduced levels of MMP-9 and VEGF during the post-surgical period. The bacterial load was reduced immediately after therapy, but recolonization was observed by 4 weeks in both groups.

INTRODUCTION:

Peri-implantitis is a prevalent chronic inflammatory disease of the peri-implant supporting tissues characterized by an accelerating pattern of disease progression (Derks et al., 2016a, 2016b; Schwarz et al., 2018). Clinical outcomes of peri-implantitis treatment remain unpredictable and reported recurrence rates are as high as 44% (Carcuac et al., 2020) and 60% (Renvert et al., 2018). Non-surgical treatment of peri-implantitis has limited efficacy (Bassetti et al., 2014; Esposito et al., 2013), due to the limited access to decontaminate the implant surface and an inability to correct bony disharmonies. Surgical interventions generally result in in more favorable outcomes for probing depth (PD) reduction (Di Gianfilippo et al., 2020; Froum et al., 2015; Khoury & Buchmann, 2001; Mercado et al., 2018) and radiographic bone gain (Deppe et al., 2007; Mercado et al., 2018; Roccuzzo et al., 2017). Notwithstanding, long-term success is often lower than 60% (Heitz-Mayfield et al., 2018; Isehed et al., 2018; Mercado et al., 2018; Ravida et al., 2022; Roccuzzo et al., 2017). Many treatment modalities have been developed and tested over the years for surgical treatment of peri-implantitis (Di Gianfilippo et al., 2020). However, no clear evidence exists to define the most predictable approach thus further research is warranted for the treatment of peri-implantitis.

Laser therapy has become a promising adjunctive tool for surgical treatment of peri-implantitis (Schwarz et al., 2009). Er:YAG (erbium-doped yttrium aluminium garnet) lasers are primarily absorbed by water, which has well-documented microbial decontamination, anti-inflammatory, and bio-stimulatory properties in various preclinical studies. Its bactericidal effects on titanium surface can reach 99% efficacy irrespective of the implant surface characteristics and without surface damage (Kreisler et al., 2002)(Giannelli et al., 2017). In addition, the use of Er:YAG lasers for implant surface decontamination during peri-implantitis therapy can aid in greater new bone-to-implant contact (BIC) in a canine model (linear bone gain: 3.37 vs. 1.83 mm; laser vs. control) (Nevins et al., 2014).

A recent randomized clinical trial from our group investigated the adjunctive use of a Er:YAG laser during surgical reconstructive treatment of peri-implantitis (Wang et al., 2021a). All patients achieved significant PD reduction up to 6 months follow-up, with the laser irradiated group showing an additional 0.8 mm of PD

reduction compared to the control group. Further research is warranted to define deeper level outcomes for early detection of subclinical signs of disease and relapse (Larsson et al., 2016; Wang et al., 2021b). Analysis of protein biomarkers has gained attention as a non-invasive diagnostic tool for detection of subclinical signs of disease through analysis of pro-inflammatory mediators (eg. Interleukin 1β, IL-1β), tissue remodeling matrix metalloproteinase (MMPs), signals related to angiogenesis (vascular endothelial growth factors, VEGF) or cell proliferation amongst others (Giannobile et al., 1995; Kinney et al., 2014; Li & Wang, 2014; Oringer et al., 1998; Steigmann et al., 2020; Tatarakis et al., 2014). Cross sectional studies using peri-implant crevicular fluid (PICF) reported high sensitivity and specificity for IL-1β and tissue inhibitor metalloproteinase (TIMP)-2 to differentiate healthy and diseased peri-implant tissues (Wang et al., 2016). Longitudinal investigations reported that IL-1β as well as VEGF correlated with peri-implant disease severity (Renvert et al., 2015). In addition, IL-1β, VEGF and IL-6 were found to be reduced in patients with successful disease resolution (Renvert et al., 2017). Therefore, regulators of the upstream immune and inflammatory response such as IL-1 β, of collagen cycle such as MMPs/TIMPs, and revascularization factors as VEGF are among the most investigated and promising biomarkers for detection of subclinical peri-implant disease.

Human research on the effect of Er:YAG lasers on surgical treatment of peri-implantitis is scarce and, to the best of our knowledge, no studies have reported on the longitudinal changes of protein biomarkers and bacterial recolonization after laser-assisted surgical treatment. Therefore, the primary aim of the present study was to investigate the impact of the adjunctive use of an Er:YAG laser in reconstructive therapy regarding bacterial decontamination and inflammatory modulation. Our secondary aim was to explore the dynamic changes of bacterial pathogens and protein biomarkers in the peri-implant crevicular fluid as an assessment of the healing process.

MATERIALS AND METHODS:

The study was conducted in fully accordance with the Helsinki Declaration as revised in 2013 and compliant with the Consolidated Standards of Reporting Trials (CONSORT) guidelines. The study was approved by the

local ethical committee Health Science Institutional Review Board (HUM00124386) and registered on ClinicalTrials.gov (NCT03127228). This clinical trial has been published in part in Wang et al. (Wang et al., 2021a; Wang et al., 2021b). The outcomes from this same patient cohort with regard to oral fluid protein biomarker levels and microbial profiles are reported in the present study.

This study was designed as a randomized patient/examiner double-masked clinical trial on the effect of Er:YAG laser used as adjunct of a reconstructive therapy of peri-implantitis. Twenty-four systemically healthy adults with one dental implant diagnosed with peri-implantitis were recruited to join the study. Implants were considered eligible and included if presented with radiographic evidence of $\geq$ 2mm of bone loss, PD $\geq$ 5mm, positive for bleeding and/or suppuration on probing, while in function for more than 6 months (Sanz & Chapple, 2012). Patients were excluded in cases of implant mobility, current smoking, pregnancy, medications or diseases known to affect bone or connective tissue metabolism, and in cases antibiotics usage within the last two months. Half of the patients served as controls with mechanical debridement and reconstructive treatment; the other half in the test group received the same treatment as the control group plus additional irradiation with Er:YAG laser. Both patients and examiners (including sampling) were masked about the randomization. Additional details on the study design have been reported previously (Wang et al., 2021a). Each patient had a total of 6 study visits (Figure 1) that included: baseline (V1), surgical treatment of peri-implantitis (V2), 2-week and 4-week follow-ups (V3 and V4, respectively), as well as 3-month and 6-month follow-ups (V5 and V6, respectively). Bacterial plaque and peri-implant crevicular fluid (PICF) samples were collected at baseline (V1) and at every follow-up examination (V3, V4, V5 and V6). Clinical measurements and standardized radiographs were obtained at baseline (V1), at 3 and 6 months (V5 and V6). Clinical measurements were recorded by two calibrated masked examiners (MA and JK) as reported in Wang et al. (2021a). Operator calibration was conducted as described in Di Gianfilippo et al. (Di Gianfilippo et al., 2021). Inter-examiner agreement (Lin's concordance correlation coefficient, CCC) and intra-examiner agreement (intraclass correlation coefficient, ICC) were of 0.79 (CCC; 95% CI 0.74 to 0.84), 0.93 (ICC for MA; 95% CI 0.89 to 0.96), and 0.84 (ICC for JK; 95% CI 0.72 to 0.91), respectively.

Patient allocation and treatment procedures

Patients were screened and enrolled between June 2017 and May 2018. On first examination (V1) all participants signed the informed consent, received sampling of PICF and bacteria, clinical measurements, a standardized radiograph, and a periodontal maintenance. The periodontal maintenance consisted in single-session of full-mouth supragingival debridement with hand scalers and piezo instruments. The day of the surgical intervention (V2), the group allocation was revealed only to the surgeon. Patient randomization allocation was described in previous publication (Wang et al., 2021a). Patients and examiners were kept unaware of the group assignment until the end of the study. Allocation criteria and allocated sequence was concealed by the study coordinator (JK) and available only for surgeon operators during surgical intervention (CWW, HLW).

All surgical procedures were performed by two expert board-certified periodontists (CWW, HLW) between 2017 and 2018 in the Department of Periodontics and Oral Medicine of the University of Michigan. All patients received surgical reconstructive treatment of peri-implantitis, with the adjunct of laser for the test group. Details of the surgical intervention have been previously published (Wang et al., 2021a). Of note, implants allocated in the test group received Er:YAG laser irradiation for removal of granulation tissue from the infrabony defect, implant surface decontamination and tissue modulation. Surface decontamination of test patients was performed with the laser using slow 0.5 mm/sec vertical and horizontal linear movements (panel setting: 50mJ/pulse, 25 pps). Low-energy laser was also applied over the bony defect and flap inner tissue (panel setting 30mJ/pulse, 20 pps). A simulated placebo laser treatment was performed in the mouth of patients allocated to the control group with irradiation of a wet gauze placed over the vestibule close to the implant location.

After degranulation and decontamination, a bone wax was placed to protect the infrabony defect from titanium particles when implantoplasty of the suprabony threads was performed. Then, the infrabony component of the defect was grafted with bone allograft particulate (MinerOss and Grafton, BioHorizons, Alabama, USA) and covered with an absorbable acellular dermal matrix (ADM) membrane (Alloderm GBR, BioHorizons, Alabama, USA). Tension-free primary closure was performed with polytetrafluoroethylene (PTFE) sutures (Cytoplast, BioHorizons, Alabama, USA) and the wound was protected with a surgical dressing (Coe-Pak Periodontal

Dressing, Patterson Dental, Minnesota, USA). All patients were provided with antibiotics (Amoxicillin, 500 mg tabs, 3 times/day for ten days) and analgesic non-steroidal anti-inflammatory drugs (Ibuprofen 600 mg tabs, prn). All patients were followed at 2 weeks and at 4 weeks for dressing and suture removal. They also returned for follow-up visits at 3 months and at 6 months after the intervention, when they received clinical and radiographic examination and a non-surgical maintenance.

Peri-implant crevicular fluid sampling and processing

PICF was collected with sterile paper strips from the deepest pocket of each implant at baseline examination (V1), 2 weeks (V3), 4 weeks (V4), 3 months (V5) and 6 months (V6) after surgical intervention. Crown surfaces were isolated by cotton rolls and gently dried with air. A single sterile paper strip (Oraflow Inc., Smithtown, NY, USA) was inserted in a standardized interproximal site until mild resistance from the pocket was felt and left stable in place for 30 seconds. After removal, a waiting period of 90 seconds elapsed before the next sampling. The process was repeated until collection of two samples without evident blood contamination. Finally, samples were placed into a sterile polypropylene tube and stored at -80◦C.

PICF samples were processed all at once after the conclusion of the clinical portion of the study. A 20 μl extraction solution (10 mg/ml aprotinin, 1 mM phenylmethylsulfonyl fluoride, and 0.1% human serum albumin in phosphate-buffered saline) was pipetted directly onto the cellulose portion of each PICF strip and secured at the top of a 12 x 75 mm polystyrene culture tube using a cap to hold it in place. The tubes holding the paper strips were centrifuged at 2000 rpm at 4°C for 5 min. Each strip was washed and centrifuged five times to obtain a total elution volume of 100 μl. The samples were then stored at -80°C until array analysis and scanning was performed according to the manufacturer's protocol (RayBiotech, Norcross, GA).

Bacterial plaque sampling and processing

Bacterial plaque and DNA were also collected with sterile paper cones from each implant at V1, V3, V4, V5 and V6 immediately after PICF sampling. Sterile paper cones were inserted deep into the pocket in standardized

interproximal sites. Sterile cones were left for 30s in place, and after removal, a wait period of 90 seconds elapsed before the second sampling. Samples were placed into a sterile tube containing RNA 500 μl of stabilizing buffer and stored at -20∘C.

The collected bacterial samples were processed all at once after the end of the clinical phases of the study. Each paper cone was transferred to a Power Bead Lysis Tube with 200μl of the pellet and supernatant. DNA extraction was performed using DNeasy PowerSoil Kit (Qiagen, Shallowater, TX, USA) and the final DNA elution was carried out in 100ul of kit-provided C6 solution. DNA quantity and quality were determined using a NanoDrop2000 (Thermo Scientific, Shallowater, TX, USA). 1.0 μL of the template DNA was used to perform the qPCR reaction using Taqman® Master Mix (Applied Biosystems, Shallowater, TX, USA) in StepOnePlus Real-Time PCR System (Applied Biosystems, Shallowater, TX, USA). Bac2F and Bac2R primers and the corresponding Bac2 probe were used for the reaction. DNA from Escherichia coli was used as a standard. The sample was run on quantitative PCR in triplicate. The PCR reaction was carried out with an initial holding stage of 50°C for 2 minutes followed by 95°C for 10 minutes. The cycling stage consisted of 40 cycles of 95°C for 15 seconds, followed by 60°C for 1 minute.

Statistical analysis

The overall trend of protein biomarker level and the laser treatment effect on protein biomarker levels during the healing process represented the primary outcomes of this study, and they were assessed using the generalized estimating equations (GEE) model through the R package 'geepack' (Højsgaard et al., 2006). To overcome the large variance and non-normality of the bacterial profiles, we assessed the statistical significance of the overall trend of bacterial profiles and the effect of the laser on bacterial levels during the healing process using a non-parametric longitudinal data model as implemented in the R package 'nparLD' (Noguchi et al., 2012), followed by the Benjamin-Hochberg method for multiple tests correction. To assess the statistical significance of overall protein biomarker levels/bacterial profile differences between different times, ANOVA was conducted. Post hoc paired t-tests were performed to identify significant protein biomarker/bacterial changes between time points. To assess the laser treatment effect at different time points, post hoc two-sample t-tests were conducted. Pearson

Correlation was used to estimate the relationship among protein biomarkers, bacterial profiles and clinical measurements. The original power calculation of the trial was based on clinical parameters provided in Wang et al. (Wang et al., 2021a).

RESULTS

Twenty-four patients (age: 64.9 ±11.2 years; 14 males 10 females) were enrolled and randomly assigned to test (n=12) and control (n=12) groups. Groups were homogeneous regarding baseline demographic and clinical variables. All patients received their predetermined treatment without protocol deviation and completed the 6 months of follow-up without dropout. No implants were lost leading to a survival rate of 100% within the study period. Baseline demographics, clinical characteristics and outcomes were previously reported in Wang et al. (Wang et al., 2021a).

Protein biomarker analysis

Levels of IL-1β and MMP-9 from the twenty-four patients showed a significant fluctuation over the healing phase and follow-up visits ($p<0.0001$ and $p<0.001$ respectively; Supplementary Figure 1). IL-1β was associated with a 25% increase at 2 weeks after surgical intervention and a 50% reduction between 2 and 4 weeks ($p<0.0001$). Similarly, MMP-9 increased 10% during the first 2 weeks and decreased 16% to levels lower than baseline at 4 weeks ($p<0.05$). IL-1β and MMP-9 remained stable for the following examinations without any statistically significant fluctuation. Although there was no significant peak increase, VEGF level significantly decreased over time ($p<0.05$) with a more notable reduction that occurred between 2 and 4 weeks (155.3 ± 27.0 vs. 86.2 ± 14.2 pg/ml; 2 vs 4 weeks) despite ANOVA measures between individual timepoints being non-significant (Supplementary Figure 1).

Surface disinfection with Er:YAG laser produced reduced levels of protein biomarkers at all four timepoints compared to the control intervention, with statistical significance achieved for MMP-9 ($p<0.01$) and VEGF ($p<0.05$) (Figure 2). Laser disinfection attenuated the postoperative peak increase of IL-1β but statistical

significance was not achieved (2 weeks, test vs. control: p=0.08). MMP-9 and VEGF levels were successfully reduced by laser treatment (p<0.01), with statistical significance that was maintained for MMP-9 at the last follow-up examination (p<0.001).

Bacterial Load and microbial profile analysis

Reconstructive surgical treatment of peri-implantitis successfully reduced total bacterial load for the full cohort, especially at two weeks (p<0.05, Figure 3). Overall bacterial load decreased nearly 2 folds during the 2 weeks following the intervention (6.5±9.9 vs. 3.3±5.8 ng/µl; baseline vs. 2 weeks); however, bacteria recolonized to pre-operative levels as early as 4 weeks. When individual red-complex pathogens from the twenty-four patients were tested (Supplementary Figure 2), *Tannerella forsythia* and *Treponema denticola* were significantly decreased by the treatment at 2 weeks (*T. forsythia*: p<0.0001; *T. denticola*: p<0.01), while *Porphyromonas gingivalis* level remained unchanged (*P. gingivalis*, p=0.1). *T. forsythia* and *T. denticola* responded similarly to the surgical treatment between baseline and 2 weeks (bacterial count decreased by 5.8 times for *T. forsythia* and 13.5 times for *T. denticola*), and remained stable at a low level between 2 and 4 weeks. However, both of these periopathogens recolonized to pre-operative relative ratio between 4 weeks and 3 months (Supplementary Figure 2). No significant time effect was noted for other bacteria, with the exception of *Streptococcus mutans* (p<0.01) and *Fusobacterium nucleatum* (p<0.05) which decreased after the intervention to recolonize after 6 months.

The Er:YAG laser did not significantly alter the microbial profile, despite a trend noted with reduced load for the test group. The average total bacteria counts were lower at 2 weeks in the test group compared to the control (19.6±28.2 vs. 49.6±79.1 µg/µl; test vs. control; p=0.2) but did not reach statistical significance.

Correlations among protein biomarkers, microbial profiles and clinical variables.

Pearson heatmap analysis showed strong correlations between protein biomarker and bacterial pathogens. Positive correlations existed among pro-inflammatory mediators, and positive correlations were noted among bacterial pathogens. Negative correlations existed between anti-inflammatory cytokines and microbial

pathogens, or between early bacterial colonizers and pro-inflammatory mediators (Figure 4). A positive correlation linked pro-inflammatory mediators, such that IL-1β, with MMP-9 (r:0.52) and VEGF (r:0.52); and MMP-9 with VEGF (r:0.44). A positive correlation was also revealed among red-complex pathogens; *T. forsythia* correlated with *P. gingivalis* (r:0.31) and *T. denticola* (r:0.40). Total bacterial load was positively correlated with *T. denticola* (r:0.29) and *Prevotella intermedia* (r:0.28). Correlations were noted between bacterial colonizers and protein biomarker levels. In particular, a positive correlation was noted between *F. nucleatum* and IL-1β (r:0.23), MMP-9 (r:0.30) and VEGF (r:0.23). Negative correlation existed between early colonizers and pro-inflammatory mediators, as well as between bacterial pathogens and anti-inflammatory cytokines. *S. mutans* negatively correlated with IL-1β (r:-0.34), MMP-9 (r:-0.14) and VEGF (r:-0.12).

Pearson correlation analysis was used to determine if protein biomarker as well as specific bacteria correlated with changes in clinical variables between baseline and 6 months. *P. gingivalis* negatively correlated with mean PD reduction (r = -0.50, p = 0.01) and deepest PD reduction (r = -0.41, p = 0.05) with statistical significance. A negative correlation was noted between the 6-month mean PD reduction and IL-1β (r:-0.24), MMP-9 (r:-0.21), and *T. denticola* (r:-0.15), but such correlations did not reach statistical significance (Supplementary Figure 3). Similarly, a non-statistically significant negative correlation was noted between the 6-month reduction of the deepest PD site and IL-1β (r:-0.24), and *T. denticola* (r:-0.31) (Supplementary Figure 4). A composite clinical definitions of treatment failure was created as PD ≥ 6mm and radiographic bone loss ≥ 3mm and positive bleeding on probing at 6 months, and tested with the investigated variables. None of the selected protein biomarkers and microbial pathogens were significantly associated with the treatment failure except for *T. denticola*. When the 24-week-level of *T. denticola* is lower than baseline, there is higher chance the case will satisfy the definition of treatment failure (p=0.051).

DISCUSSION

The present randomized clinical trial investigated the longitudinal changes of protein biomarkers as well as bacterial load from peri-implantitis lesions treated with reconstructive therapy with or without the adjunctive use

of Er:YAG laser. In general and within the included cohort, selected protein biomarker levels fluctuated with an immediate postoperative increase followed by a decrease to a level lower than at baseline. Additional laser application for the test group significantly impacted the levels of MMP-9 and VEGF in PICF up to 6 months follow-up. The increase of the IL-1 at two-weeks post-op was attenuated in the laser group compared to control, but the use of laser did not influence its level after 3 and 6 months. Bacterial counts reduced after therapy in both groups without statistically significant differences between treatment modalities.

Reported literature exploring protein biomarkers for peri-implant disease diagnostics is mostly composed of cross-sectional studies (Darabi et al., 2013; Faot et al., 2015; Ghassib et al., 2019; Gurlek et al., 2017; Rakic et al., 2020; Rakic et al., 2014; Severino et al., 2016; Severino et al., 2011; Wang et al., 2016; Zani et al., 2016); while prospective studies with intervention and longitudinal observation are limited. In an experimental peri-implant mucositis model, IL-1β level and clinical signs of inflammation changed to reflect the phases of the study with an increase during the plaque-accumulation period, followed by a decrease during the resolution phases (Chan et al., 2019). In a prospective trial on non-surgical treatment of peri-implantitis, lower levels of IL-1β and VEGF were documented from implants with favorable clinical outcomes when compared with poor-responders (6 months after treatment, good vs. bad responders: IL-1β: 88.4 ± 98.5 vs. 496.7 ± 684.3; VEGF: 242.3 ± 169.7 vs. 568.4 ± 428.6) (Renvert et al., 2017). Interestingly, stable outcomes were achieved in only 22% of the treated patients and the authors speculated that the non-surgical modality of intervention was insufficient in terms of access to allow for a proper debridement of the contaminated implant surface. As compared to Renvert et al's cohort, the patients included in the present study presented with more advanced peri-implantitis lesion, and received surgical treatment for peri-implantitis that allowed adequate access for removal of bacterial biofilm and debridement of inflamed peri-implant tissue, resulting in improved outcomes after therapy. The levels of IL-1β, MMP-9 and VEGF correspond to the healing after reconstructive surgery with a postoperative peak at 2 weeks, followed by a gradual decrease during the longer-term follow-up. Measurements for these biomarkers at 6 months post-operative were lower than those at baseline. In line with the existing evidence, the present study validated that the levels of protein biomarkers can reliably track phases of wound healing and correlate with the level of clinical inflammation.

Despite the significant variation of protein biomarker levels, statistically significant differences observed between laser-treated and non-laser-treated patients for MMP-9 and VEGF were sustained even after 6 months follow-up.

Microbiological research of peri-implantitis pathogenic flora have traditionally targeted the well-studied red complex pathogens and a subset of species from the orange complex. Many authors have previously reported that levels of *T. denticola*, *T. forsythia* and *P. gingivalis* were increased in peri-implantitis samples compared to those in healthy mucosa (da Silva et al., 2014; Koyanagi et al., 2013; Monje et al., 2020; Polymeri et al., 2021; Sanz-Martin et al., 2017; Shi et al., 2022; Shibli et al., 2008). Many authors also agreed on the role that orange complex pathogens play in bridging together different species and contributing towards the maturation of the peri-implant microbial community (Ghensi et al., 2020; Kroger et al., 2018; Lafaurie et al., 2017; Monje et al., 2020; Sanz-Martin et al., 2017). In the present cohort, surgical reconstructive therapy for treatment of peri-implantitis successfully reduced PD, as well as the total bacterial load and the relative percentage of pathogens within the residual biofilm. While overall reconstitution of the baseline biofilm took 4 weeks, red and orange complex pathogens recolonized over the following 3 to 6 months. Other human trials with clinical and microbiological evaluation supported the results of the present study as the overall bacterial count was reduced only in the short term (Hallstrom et al., 2017) while the count of specific pathogens remained at lower levels over the course of 3-6 months (Bassetti et al., 2014). Our results also suggest that early biofilms are less pathogenic as reflected by lower levels of red and orange complex bacteria, and open the field to future directions related to personalized maintenance care (Nieri et al., 2020). In a recently published parallel study (Wang et al., 2021b), machine-learning clustering of peri-implant immune infiltrate predicted the outcome of surgical therapy and correlated with the alpha Faith's phylogenetic diversity. Patients with favorable immunolandscape signature (increased M1/M2 macrophage ratio) had reduced recolonization of pathogenic bacterial species and improved treatment outcome after 6 months.

In the present study, PICF was used to monitor the inflammatory/immune processes because of its non-invasive and fast collection, as well as because the possibility to obtain multiple samples from the same implant over different timepoints. In general, positive correlations were noted between IL-1β and bacterial pathogens. IL-1β positively correlated with MMP-9 and VEGF; this is not surprising as inflammation is a well-orchestrated event

coordinated by multiple inflammatory mediators that act synchronously (Hajishengallis et al., 2020). IL-1 is a known inducer for VEGF and MMPs (Inoue et al., 2005) and actively contributes to tissue metabolism through matrix degradation and neoangiogenesis. As for the bacterial-host interaction, *F. nucleatum* positively correlated with IL-1β, MMP-9 and VEGF. This is not surprising either as *F. nucleatum* has potential for activation of Triggering Receptor Expressed on Myeloid Cells (TREM-1), a macrophage-surface receptor involved in the propagation of the inflammation in response to bacterial challenge (Bouchon et al., 2001; Lagha & Grenier, 2016). Of notice, IL-1β, MMP-9 and VEGF positively correlated with *F. nucleatum* but negatively correlated with *S. mutans*, an early colonizer classically associated with symbiotic biofilm. This stresses the existence of a close interrelationships between pathogenic microflora and evoked inflammatory response. However, among red complex pathogens, limited correlations were found with the levels of IL-1β, MMP-9 and VEGF; only *T. denticola* showed slight positive correlation with IL-1β. This conflicts with previous literature supporting increased expression of pro-inflammatory mediators in response to *P. gingivalis*, *T. forsythia* and *T. denticola* (Holt & Ebersole, 2005). Of note, this study includes samples following surgical therapy of peri-implantitis, and the treatment has significantly reduced the levels of those pathogen. Future mechanistic investigations are needed to clarify the interactions between the host and microbiome. Pro-inflammatory mediators and pathogenic bacteria negatively correlated with reduction in mean PD and deepest PD over the observation period. Furthermore, levels of *T. denticola* associated with treatment failure, defined as PD $\geq$ 6mm and radiographic bone loss $\geq$ 3mm and positive bleeding on probing at 6 months after therapy. These findings reinforce and furtherly expand the literature previously published by Renvert et al., when bacteria and protein biomarkers successfully discriminated patients with favorable vs. unfavorable clinical outcomes 6 months after peri-implant non-surgical therapy (Renvert et al., 2017).

The present clinical trial is the first human longitudinal investigation on the changes of protein biomarkers and bacterial profile after reconstructive treatment of peri-implantitis based on the existing literature. It is also the first human longitudinal investigation on the effect of adjunctive Er:YAG laser treatment on protein biomarker and bacterial profiles after surgical treatment of peri-implantitis.

A limitation of the study is the reduced sample size that did not allow adjustment of the analysis based on local factors that may have impacted the recolonization of the local microflora, like implant surface characteristics, implant neck macrodesign or restoration contours. In the light of the obtained results, post-hoc analyses were used based on the 6-month outcomes of MMP-9, IL-1β and VEGF, with 12 patients each group and α=0.05. Post-hoc analysis for MMP-9 resulted in a power of 0.8761, proving that the included sample size is adequate for analysis of MMP-9. On the other hand, IL-1β and VEGF resulted in a power lower than 0.8. A priori sample size was then calculated with the 6-month levels of IL-1β and VEGF, with a pre-set power of 0.8 and α=0.05, which resulted to be of 31 patients in each group for IL-1β, and 20 patients each group for VEGF. As being the first study on biomarker evaluation after reconstructive therapy of peri-implantitis with laser vs. mechanical therapy, it was not possible to conduct a priori sample size calculation based on the selected biomarkers, looking at the existing literature. However, results of our pilot trial will help upcoming research by guiding towards a more accurate determination of the sample size for MMP-9, IL-1β and VEGF from peri-implant crevicular fluid after reconstructive therapy of peri-implantitis.

Another limitation of the study is the use of the definition of peri-implantitis as proposed during the VIII European Workshop in Periodontology (PD ≥ 5mm, bone loss ≥ 2mm, positive for bleeding/suppuration on probing; Sanz and Chapple 2012), that is more permissive than the case definition reported during the 2017 World Workshop on Periodontal and Peri-implant Diseases and Conditions (PD ≥ 6mm, bone loss ≥ 3mm, positive for bleeding/suppuration on probing; Berglundh et al. 2018).

Future study projects, designed after the 2017 World Workshop, will enroll larger sample sizes and adopt the most recent case definition of peri-implantitis. Future studies will further investigate the clinical implications of protein biomarkers and bacteria as adjunctive informative diagnostics to peri-implantitis, and will provide more in-depth assessment of the treatment outcome pertinent to the stability and progression of the disease. Future studies will also propose absolute cutoff levels for protein biomarkers and bacteria able to discriminate peri-implant pathology.

In conclusion and within the discussed limitations, levels of protein biomarker from the peri-implant crevicular fluid and bacterial load from the peri-implant sulcus change after surgical reconstructive treatment of peri-implantitis reflecting the phases of inflammation and healing. Additional irradiation with Er:YAG laser can modulate the inflammatory response through reduced levels of MMP-9 and VEGF during the post-surgical period. Although surgical reconstructive treatment of peri-implantitis successfully reduced the overall bacterial load, recolonization occurred after 4 weeks.

LEGEND:

Figure 1: Randomized clinical trial study design. Twenty-four patients satisfied the inclusion criteria and attended a total of six study visits and followed-up for six months. All patients were treated with surgical reconstructive therapy with (n=12) or without (n=12) Er:YAG laser irradiation. Peri-implant crevicular fluid and bacterial plaque samples were collected pre-operatively and during four post-operative visits throughout a ix-month period.

Figure 2: Longitudinal changes of interleukin-1β (IL-1β), matrix metalloproteinase (MMP)-9 and vascular endothelial growth factors (VEGF) for the two treatment groups during the healing process after surgical reconstructive therapy of peri-implantitis. Data was presented as mean ± standard error. Statistical significance was reported for between-group comparisons and was indicated as follows: * $p < 0.05$; ** $p < 0.001$.

Figure 3: Total bacterial load for the whole cohort of patients (A) and the comparison for the two treatment groups (B) at baseline and over a period of six months after reconstructive treatment of peri-implantitis. The inter-group difference at the critical two weeks follow-up between control and experimental laser group was shown (C). The trend for panel A ($p < 0.01$) indicated the overall significance for variation during the follow-up period.

Figure 4: Heatmap correlation among total bacterial load, bacterial species and protein biomarkers. Each box is positioned at the intersection of the respective target, and it is colored with Pearson Correlation spectrum scale. The red color indicates positive correlation and the blue color negative correlation. The intensity of the color represents the strength of the correlation.

Abbreviations. Pg: Porphyromonas gingivalis, Tf: Tannerella forsythia, Td: Treponema denticola, Fn: Fusobacterium nucleatum, Sm: Streptococcus mutans, IL-1β: interleukin-1β, MMP-9: matrix metalloproteinases-9, VEGF: vascular endothelial growth factor.

Supplementary Figure 1: Longitudinal changes of interleukin-1β (IL-1β), matrix metalloproteinase (MMP)-9 and vascular endothelial growth factors (VEGF) for all study patients over 6 months after surgical reconstructive therapy of peri-implantitis. Data was presented as mean ± standard error. Statistical significance for within-group longitudinal changes was indicated as follows: * $p < 0.05$; *** $p < 0.0001$; # $p < 0.05$.

Supplementary Figure 2: Pathogen load at baseline and longitudinal changes over a period of 6 months for Treponema denticola (A and B) and Tannerella forsythia (C and D), Porphyromonas gingivalis (E and F) and Fusobacterium nucleatum (G and H). Thicker lines were used for the averaged means, smaller dots and thinner lines indicated individual patients. Panels A, C, E and G evaluated the bacterial change for the whole cohort of patients; panels B, D, F and H investigated the effect of the adjunctive laser treatment on the bacterial changes. Statistical significance was indicated as follows: * $p < 0.05$; **** $p < 0.0001$; # $p < 0.05$; ### $p < 0.001$; #### $p < 0.0001$. Trend indicated the overall significance for variation during the follow-up period.

Supplementary Figure 3: Pearson Correlation analyses between interleukin-1β (IL1-β), matrix metalloproteinases-9 (MMP-9), Porphyromonas gingivalis (Pg), Tannerella forsythia (Tf), and Treponema denticola (Td) in relation to mean probing depth changes (left panels). Interaction effect between treatment modality (Laser vs. Control) and IL1-β, MMP-9, Pg, Tf, and Td (right panels).

Supplementary Figure 4: Pearson Correlation analyses between interleukin-1β (IL1-β), matrix metalloproteinases-9 (MMP-9), Porphyromonas gingivalis (Pg), Tannerella forsythia (Tf), and Treponema denticola (Td) in relation to deepest probing depth changes (left panels). Left panels: Interaction effect between treatment modality (Laser vs. Control) and IL1-β, MMP-9, Pg, Tf, and Td (right panels).

REFERENCES:

Aoki, A., Mizutani, K., Schwarz, F., Sculean, A., Yukna, R. A., Takasaki, A. A., . . . Izumi, Y. (2015). Periodontal and peri-implant wound healing following laser therapy. *Periodontol 2000, 68*(1), 217-269. doi:10.1111/prd.12080

Bassetti, M., Schar, D., Wicki, B., Eick, S., Ramseier, C. A., Arweiler, N. B., . . . Salvi, G. E. (2014). Anti-infective therapy of peri-implantitis with adjunctive local drug delivery or photodynamic therapy: 12-month outcomes of a randomized controlled clinical trial. *Clin Oral Implants Res, 25*(3), 279-287. doi:10.1111/clr.12155

Bouchon, A., Facchetti, F., Weigand, M. A., & Colonna, M. (2001). TREM-1 amplifies inflammation and is a crucial mediator of septic shock. *Nature, 410*(6832), 1103-1107. doi:10.1038/35074114

Carcuac, O., Derks, J., Abrahamsson, I., Wennstrom, J. L., & Berglundh, T. (2020). Risk for recurrence of disease following surgical therapy of peri-implantitis-A prospective longitudinal study. *Clin Oral Implants Res, 31*(11), 1072-1077. doi:10.1111/clr.13653

Chan, D., Pelekos, G., Ho, D., Cortellini, P., & Tonetti, M. S. (2019). The depth of the implant mucosal tunnel modifies the development and resolution of experimental peri-implant mucositis: A case-control study. *J Clin Periodontol, 46*(2), 248-255. doi:10.1111/jcpe.13066

da Silva, E. S., Feres, M., Figueiredo, L. C., Shibli, J. A., Ramiro, F. S., & Faveri, M. (2014). Microbiological diversity of peri-implantitis biofilm by Sanger sequencing. *Clin Oral Implants Res, 25*(10), 1192-1199. doi:10.1111/clr.12231

Darabi, E., Kadkhoda, Z., & Amirzargar, A. (2013). Comparison of the levels of tumor necrosis factor-alpha and interleukin-17 in gingival crevicular fluid of patients with peri-implantitis and a control group with healthy implants. *Iran J Allergy Asthma Immunol, 12*(1), 75-80. doi:012.01/ijaai.7580

Deppe, H., Horch, H. H., & Neff, A. (2007). Conventional versus CO2 laser-assisted treatment of peri-implant defects with the concomitant use of pure-phase beta-tricalcium phosphate: a 5-year clinical report. *Int J Oral Maxillofac Implants, 22*(1), 79-86.

Derks, J., Schaller, D., Hakansson, J., Wennstrom, J. L., Tomasi, C., & Berglundh, T. (2016a). Effectiveness of Implant Therapy Analyzed in a Swedish Population: Prevalence of Peri-implantitis. *J Dent Res, 95*(1), 43-49. doi:10.1177/0022034515608832

Derks, J., Schaller, D., Hakansson, J., Wennstrom, J. L., Tomasi, C., & Berglundh, T. (2016b). Peri-implantitis - onset and pattern of progression. *J Clin Periodontol, 43*(4), 383-388. doi:10.1111/jcpe.12535

Di Gianfilippo, R., Askar, H., Henderson, J., Franceschi, D., Wang, H. L., & Wang, C. W. (2021). Intra- and Inter-Examiner Repeatability of Diagnostic Peri-implant Clinical Measurement: A Pilot Study. *J Oral Implantol*. doi:10.1563/aaid-joi-D-20-00160

Di Gianfilippo, R., Sirinirund, B., Rodriguez, V. M., Chen, Z., & Wang, H.-L. (2020). Long-Term Prognosis of Peri-Implantitis Treatment: A Systematic Review of Prospective Trials with More Than 3 Years of Follow-Up. *Appl. Sci., 10*(24), 9084. doi:10.3390/app10249084

Esposito, M., Grusovin, M. G., De Angelis, N., Camurati, A., Campailla, M., & Felice, P. (2013). The adjunctive use of light-activated disinfection (LAD) with FotoSan is ineffective in the treatment of peri-implantitis: 1-year results from a multicentre pragmatic randomised controlled trial. *Eur J Oral Implantol, 6*(2), 109-119.

Faot, F., Nascimento, G. G., Bielemann, A. M., Campao, T. D., Leite, F. R., & Quirynen, M. (2015). Can peri-implant crevicular fluid assist in the diagnosis of peri-implantitis? A systematic review and meta-analysis. *J Periodontol, 86*(5), 631-645. doi:10.1902/jop.2015.140603

Froum, S. J., Froum, S. H., & Rosen, P. S. (2015). A Regenerative Approach to the Successful Treatment of Peri-implantitis: A Consecutive Series of 170 Implants in 100 Patients with 2- to 10-Year Follow-up. *Int J Periodontics Restorative Dent, 35*(6), 857-863. doi:10.11607/prd.2571

Ghassib, I., Chen, Z., Zhu, J., & Wang, H. L. (2019). Use of IL-1 beta, IL-6, TNF-alpha, and MMP-8 biomarkers to distinguish peri-implant diseases: A systematic review and meta-analysis. *Clin Implant Dent Relat Res, 21*(1), 190-207. doi:10.1111/cid.12694

Ghensi, P., Manghi, P., Zolfo, M., Armanini, F., Pasolli, E., Bolzan, M., . . . Segata, N. (2020). Strong oral plaque microbiome signatures for dental implant diseases identified by strain-resolution metagenomics. *NPJ Biofilms Microbiomes, 6*(1), 47. doi:10.1038/s41522-020-00155-7

Giannelli, M., Bani, D., Tani, A., Materassi, F., Chellini, F., & Sassoli, C. (2017). Effects of an Erbium:Yttrium-Aluminum-Garnet Laser and Ultrasonic Scaler on Titanium Dioxide-Coated Titanium Surfaces Contaminated With Subgingival Plaque: An In Vitro Study to Assess Post-Treatment Biocompatibility With Osteogenic Cells. *J Periodontol, 88*(11), 1211-1220. doi:10.1902/jop.2017.170195

Giannobile, W. V., Lynch, S. E., Denmark, R. G., Paquette, D. W., Fiorellini, J. P., & Williams, R. C. (1995). Crevicular fluid osteocalcin and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP) as markers of rapid bone turnover in periodontitis. A pilot study in beagle dogs. *J Clin Periodontol, 22*(12), 903-910. doi:10.1111/j.1600-051x.1995.tb01793.x

Gurlek, O., Gumus, P., Nile, C. J., Lappin, D. F., & Buduneli, N. (2017). Biomarkers and Bacteria Around Implants and Natural Teeth in the Same Individuals. *J Periodontol, 88*(8), 752-761. doi:10.1902/jop.2017.160751

Hajishengallis, G., Chavakis, T., & Lambris, J. D. (2020). Current understanding of periodontal disease pathogenesis and targets for host-modulation therapy. *Periodontol 2000, 84*(1), 14-34. doi:10.1111/prd.12331

Hallstrom, H., Persson, G. R., Lindgren, S., & Renvert, S. (2017). Open flap debridement of peri-implantitis with or without adjunctive systemic antibiotics: A randomized clinical trial. *J Clin Periodontol, 44*(12), 1285-1293. doi:10.1111/jcpe.12805

Heitz-Mayfield, L. J., Salvi, G. E., Mombelli, A., Loup, P. J., Heitz, F., Kruger, E., & Lang, N. P. (2018). Supportive peri-implant therapy following anti-infective surgical peri-implantitis treatment: 5-year survival and success. *Clin Oral Implants Res, 29*(1), 1-6. doi:10.1111/clr.12910

Højsgaard, S., Halekoh, U., & Yan, J. (2006). The R Package geepack for Generalized Estimating Equations. *Journal of Statistical Software, 15*(2), 1-11.

Holt, S. C., & Ebersole, J. L. (2005). Porphyromonas gingivalis, Treponema denticola, and Tannerella forsythia: the "red complex", a prototype polybacterial pathogenic consortium in periodontitis. *Periodontol 2000, 38*, 72-122. doi:10.1111/j.1600-0757.2005.00113.x

Inoue, K., Masuko-Hongo, K., Okamoto, M., & Nishioka, K. (2005). Induction of vascular endothelial growth factor and matrix metalloproteinase-3 (stromelysin) by interleukin-1 in human articular chondrocytes and synoviocytes. *Rheumatol Int, 26*(2), 93-98. doi:10.1007/s00296-004-0513-6

Isehed, C., Svenson, B., Lundberg, P., & Holmlund, A. (2018). Surgical treatment of peri-implantitis using enamel matrix derivative, an RCT: 3- and 5-year follow-up. *J Clin Periodontol, 45*(6), 744-753. doi:10.1111/jcpe.12894

Khoury, F., & Buchmann, R. (2001). Surgical therapy of peri-implant disease: a 3-year follow-up study of cases treated with 3 different techniques of bone regeneration. *J Periodontol, 72*(11), 1498-1508. doi:10.1902/jop.2001.72.11.1498

Kinney, J. S., Morelli, T., Oh, M., Braun, T. M., Ramseier, C. A., Sugai, J. V., & Giannobile, W. V. (2014). Crevicular fluid biomarkers and periodontal disease progression. *J Clin Periodontol, 41*(2), 113-120. doi:10.1111/jcpe.12194

Koyanagi, T., Sakamoto, M., Takeuchi, Y., Maruyama, N., Ohkuma, M., & Izumi, Y. (2013). Comprehensive microbiological findings in peri-implantitis and periodontitis. *J Clin Periodontol, 40*(3), 218-226. doi:10.1111/jcpe.12047

Kreisler, M., Kohnen, W., Marinello, C., Gotz, H., Duschner, H., Jansen, B., & d'Hoedt, B. (2002). Bactericidal effect of the Er:YAG laser on dental implant surfaces: an in vitro study. *J Periodontol, 73*(11), 1292-1298. doi:10.1902/jop.2002.73.11.1292

Kroger, A., Hulsmann, C., Fickl, S., Spinell, T., Huttig, F., Kaufmann, F., . . . Kebschull, M. (2018). The severity of human peri-implantitis lesions correlates with the level of submucosal microbial dysbiosis. *J Clin Periodontol, 45*(12), 1498-1509. doi:10.1111/jcpe.13023

Lafaurie, G. I., Sabogal, M. A., Castillo, D. M., Rincon, M. V., Gomez, L. A., Lesmes, Y. A., & Chambrone, L. (2017). Microbiome and Microbial Biofilm Profiles of Peri-Implantitis: A Systematic Review. *J Periodontol, 88*(10), 1066-1089. doi:10.1902/jop.2017.170123

Lagha, A. B., & Grenier, D. (2016). Tea polyphenols inhibit the activation of NF-kappaB and the secretion of cytokines and matrix metalloproteinases by macrophages stimulated with Fusobacterium nucleatum. *Sci Rep, 6*, 34520. doi:10.1038/srep34520

Larsson, L., Decker, A. M., Nibali, L., Pilipchuk, S. P., Berglundh, T., & Giannobile, W. V. (2016). Regenerative Medicine for Periodontal and Peri-implant Diseases. *J Dent Res, 95*(3), 255-266. doi:10.1177/0022034515618887

Li, J. Y., & Wang, H. L. (2014). Biomarkers associated with periimplant diseases. *Implant Dent, 23*(5), 607-611. doi:10.1097/ID.0000000000000129

Lin, G. H., Suarez Lopez Del Amo, F., & Wang, H. L. (2018). Laser therapy for treatment of peri-implant mucositis and peri-implantitis: An American Academy of Periodontology best evidence review. *J Periodontol, 89*(7), 766-782. doi:10.1902/jop.2017.160483

Mercado, F., Hamlet, S., & Ivanovski, S. (2018). Regenerative surgical therapy for peri-implantitis using deproteinized bovine bone mineral with 10% collagen, enamel matrix derivative and Doxycycline-A prospective 3-year cohort study. *Clin Oral Implants Res, 29*(6), 583-591. doi:10.1111/clr.13256

Monje, A., Eick, S., Buser, D., & Salvi, G. E. (2020). Microbial and host-derived biomarker changes during ligature-induced and spontaneous peri-implantitis in the Beagle dog. *J Periodontal Res*. doi:10.1111/jre.12797

Nevins, M., Nevins, M. L., Yamamoto, A., Yoshino, T., Ono, Y., Wang, C. W., & Kim, D. M. (2014). Use of Er:YAG laser to decontaminate infected dental implant surface in preparation for reestablishment of bone-to-implant contact. *Int J Periodontics Restorative Dent, 34*(4), 461-466. doi:10.11607/prd.2192

Nieri, M., Giuntini, V., Pagliaro, U., Giani, M., Franchi, L., & Franceschi, D. (2020). Efficacy of a U-Shaped Automatic Electric Toothbrush in Dental Plaque Removal: A Cross-Over Randomized Controlled Trial. *Int J Environ Res Public Health, 17*(13). doi:10.3390/ijerph17134649

Noguchi, K., Gel, Y., Brunner, E., & Konietschke, F. (2012). nparLD: An R Software Package for the Nonparametric Analysis of Longitudinal Data in Factorial Experiments. *Journal of Statistical Software, 50*(12).

Oringer, R. J., Palys, M. D., Iranmanesh, A., Fiorellini, J. P., Haffajee, A. D., Socransky, S. S., & Giannobile, W. V. (1998). C-telopeptide pyridinoline cross-links (ICTP) and periodontal pathogens associated with endosseous oral implants. *Clin Oral Implants Res, 9*(6), 365-373. doi:10.1034/j.1600-0501.1996.090602.x

Polymeri, A., van der Horst, J., Buijs, M. J., Zaura, E., Wismeijer, D., Crielaard, W., . . . Brandt, B. W. (2021). Submucosal microbiome of peri-implant sites: A cross-sectional study. *J Clin Periodontol, 48*(9), 1228-1239. doi:10.1111/jcpe.13502

Rakic, M., Monje, A., Radovanovic, S., Petkovic-Curcin, A., Vojvodic, D., & Tatic, Z. (2020). Is the personalized approach the key to improve clinical diagnosis of peri-implant conditions? The role of bone markers. *J Periodontol, 91*(7), 859-869. doi:10.1002/JPER.19-0283

Rakic, M., Struillou, X., Petkovic-Curcin, A., Matic, S., Canullo, L., Sanz, M., & Vojvodic, D. (2014). Estimation of bone loss biomarkers as a diagnostic tool for peri-implantitis. *J Periodontol, 85*(11), 1566-1574. doi:10.1902/jop.2014.140069

Ravida, A., Siqueira, R., Di Gianfilippo, R., Kaur, G., Giannobile, A., Galindo-Moreno, P., . . . Wang, H. L. (2022). Prognostic factors associated with implant loss, disease progression or favorable outcomes after peri-implantitis surgical therapy. *Clin Implant Dent Relat Res, 24*(2), 222-232. doi:10.1111/cid.13074

Renvert, S., Lindahl, C., & Persson, G. R. (2018). Occurrence of cases with peri-implant mucositis or peri-implantitis in a 21-26 years follow-up study. *J Clin Periodontol, 45*(2), 233-240. doi:10.1111/jcpe.12822

Renvert, S., Widen, C., & Persson, G. R. (2015). Cytokine expression in peri-implant crevicular fluid in relation to bacterial presence. *J Clin Periodontol, 42*(7), 697-702. doi:10.1111/jcpe.12422

Renvert, S., Widen, C., & Persson, R. G. (2017). Cytokine and microbial profiles in relation to the clinical outcome following treatment of peri-implantitis. *Clin Oral Implants Res, 28*(9), 1127-1132. doi:10.1111/clr.12927

Roccuzzo, M., Pittoni, D., Roccuzzo, A., Charrier, L., & Dalmasso, P. (2017). Surgical treatment of peri-implantitis intrabony lesions by means of deproteinized bovine bone mineral with 10% collagen: 7-year-results. *Clin Oral Implants Res, 28*(12), 1577-1583. doi:10.1111/clr.13028

Sanz-Martin, I., Doolittle-Hall, J., Teles, R. P., Patel, M., Belibasakis, G. N., Hammerle, C. H. F., . . . Teles, F. R. F. (2017). Exploring the microbiome of healthy and diseased peri-implant sites using Illumina sequencing. *J Clin Periodontol, 44*(12), 1274-1284. doi:10.1111/jcpe.12788

Sanz, M., & Chapple, I. L. (2012). Clinical research on peri-implant diseases: consensus report of Working Group 4. *J Clin Periodontol, 39 Suppl 12*, 202-206. doi:10.1111/j.1600-051X.2011.01837.x

Schwarz, F., Aoki, A., Sculean, A., & Becker, J. (2009). The impact of laser application on periodontal and peri-implant wound healing. *Periodontol 2000, 51*, 79-108. doi:10.1111/j.1600-0757.2009.00301.x

Schwarz, F., Derks, J., Monje, A., & Wang, H. L. (2018). Peri-implantitis. *J Periodontol, 89 Suppl 1*, S267-S290. doi:10.1002/JPER.16-0350

Severino, V. O., Beghini, M., de Araujo, M. F., de Melo, M. L. R., Miguel, C. B., Rodrigues, W. F., & de Lima Pereira, S. A. (2016). Expression of IL-6, IL-10, IL-17 and IL-33 in the peri-implant crevicular fluid of patients with peri-implant mucositis and peri-implantitis. *Arch Oral Biol, 72*, 194-199. doi:10.1016/j.archoralbio.2016.08.021

Severino, V. O., Napimoga, M. H., & de Lima Pereira, S. A. (2011). Expression of IL-6, IL-10, IL-17 and IL-8 in the peri-implant crevicular fluid of patients with peri-implantitis. *Arch Oral Biol, 56*(8), 823-828. doi:10.1016/j.archoralbio.2011.01.006

Shi, Y., Tong, Z., Zhang, Y., Si, M., & He, F. (2022). Microbial profiles of peri-implant mucositis and peri-implantitis: Submucosal microbial dysbiosis correlates with disease severity. *Clin Oral Implants Res, 33*(2), 172-183. doi:10.1111/clr.13880

Shibli, J. A., Melo, L., Ferrari, D. S., Figueiredo, L. C., Faveri, M., & Feres, M. (2008). Composition of supra- and subgingival biofilm of subjects with healthy and diseased implants. *Clin Oral Implants Res, 19*(10), 975-982. doi:10.1111/j.1600-0501.2008.01566.x

Steigmann, L., Maekawa, S., Sima, C., Travan, S., Wang, C. W., & Giannobile, W. V. (2020). Biosensor and Lab-on-a-chip Biomarker-identifying Technologies for Oral and Periodontal Diseases. *Front Pharmacol, 11*, 588480. doi:10.3389/fphar.2020.588480

Tatarakis, N., Kinney, J. S., Inglehart, M., Braun, T. M., Shelburne, C., Lang, N. P., . . . Oh, T. J. (2014). Clinical, microbiological, and salivary biomarker profiles of dental implant patients with type 2 diabetes. *Clin Oral Implants Res, 25*(7), 803-812. doi:10.1111/clr.12139

Wang, C. W., Ashnagar, S., Di Gianfilippo, R., Arnett, M., Kinney, J., & Wang, H. L. (2021a). Laser-assisted regenerative surgical therapy for peri-implantitis: A randomized controlled clinical trial. *J Periodontol, 92*(3), 378-388. doi:10.1002/JPER.20-0040

Wang, C. W., Hao, Y., Di Gianfilippo, R., Sugai, J., Li, J., Gong, W., . . . Lei, Y. L. (2021b). Machine learning-assisted immune profiling stratifies peri-implantitis patients with unique microbial colonization and clinical outcomes. *Theranostics, 11*(14), 6703-6716. doi:10.7150/thno.57775

Wang, H. L., Garaicoa-Pazmino, C., Collins, A., Ong, H. S., Chudri, R., & Giannobile, W. V. (2016). Protein biomarkers and microbial profiles in peri-implantitis. *Clin Oral Implants Res, 27*(9), 1129-1136. doi:10.1111/clr.12708

Zani, S. R., Moss, K., Shibli, J. A., Teixeira, E. R., de Oliveira Mairink, R., Onuma, T., . . . Teles, R. P. (2016). Peri-implant crevicular fluid biomarkers as discriminants of peri-implant health and disease. *J Clin Periodontol, 43*(10), 825-832. doi:10.1111/jcpe.12586

CLR_14059_Figure 1.tif

IL-1β

MMP-9

VEGF

CLR_14059_Figure 2.tif

CLR_14059_Figure 3.tif

Heatmap Pearson Correlation

CLR_14059_Figure 4.tif